Tonix Pharmaceuticals saw its shares swing wildly between gains and losses on Wednesday morning as they started to trade ...

TD Cowen reiterated its Buy rating and $20.00 price target for EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT). This aligns with the broader analyst consensus, as InvestingPro data shows analyst targets ...

LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ: NASDAQ:RARE), a $4.08 billion market cap biotechnology company with 27% revenue growth in the past year, today unveiled new data indicating ...

Acrivon Therapeutics (ACRV) announced the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device designation, BDD, for the ...

Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism.

RenovoRx's innovative RenovoCath and TAMP platform show promising clinical data. Click here to read why RNXT stock presents ...

Julie Cooke, the Chief Human Resources Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company with strong financial health according to InvestingPro metrics, ...

Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold shares of the company's common stock. According to a recent SEC filing, Roberts sold 1,457 shares on January 31 at an average price ...

Gano Kyle, the Chief Executive Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company currently rated as having GREAT financial health according to ...